Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas
NCT00703664Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2008
- Primary completion
- Dec 2017
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and vorinostat in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate up to 9 years. Started Jul 2008; status: completed.
02
Drugs
bortezomibvorinostat
03
Conditions
mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00703664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703664.